What if we could diagnose risk for Alzheimer’s before symptoms appeared? To address the challenge, in the Laboratory of Neurosciences at the IRP, Dr. Maja Mustapic searches for Alzheimer’s biomarkers using liquid biopsies.
“I kind of made it a mission of mine to find out as much as I can, what’s available out there as treatments, trials,” John says, “and just my way of giving back, whether it helps me directly or somebody who comes after me.”
When you hear “biomarker,” what is the first thing that comes to mind? BRCA1? Fluorescently labeled G-proteins? Those are two well-known examples, but biomarkers (short for “biological markers”) are actually a much broader group of biological signs than just genetic or cellular traits.